MoneyWorks4Me

Sandu Pharmaceutical - Quaterly Results

13 Aug 2025 Evaluate
Revenue showed a marginal decline at Rs. 166.99 millions. For the quarter ended June 2025, as compared to corresponding quarter of last year.A comparatively good net profit growth of 34.34% to Rs. 2.23 millions was reported for the quarter ended June 2025 compared to Rs. 1.66 millions of previous same quarter.Operating profit for the quarter ended June 2025 rose to 5.42 millions as compared to 4.51 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 166.99 170.45 -2.03 166.99 170.45 -2.03 671.92 672.81 -0.13
Other Income 0.18 0.45 -60.00 0.18 0.45 -60.00 1.68 4.21 -60.10
PBIDT 5.42 4.51 20.18 5.42 4.51 20.18 29.30 27.18 7.80
Interest 0.26 0.21 23.81 0.26 0.21 23.81 1.03 0.63 63.49
PBDT 5.16 4.30 20.00 5.16 4.30 20.00 28.27 26.55 6.48
Depreciation 1.78 1.59 11.95 1.78 1.59 11.95 6.71 5.83 15.09
PBT 3.38 2.71 24.72 3.38 2.71 24.72 21.56 20.72 4.05
TAX 1.15 1.05 9.52 1.15 1.05 9.52 6.07 6.12 -0.82
Deferred Tax 0.06 0.29 -79.31 0.06 0.29 -79.31 0.18 0.25 -28.00
PAT 2.23 1.66 34.34 2.23 1.66 34.34 15.49 14.60 6.10
Equity 96.61 96.61 0.00 96.61 96.61 0.00 96.61 96.61 0.00
PBIDTM(%) 3.25 2.65 22.67 3.25 2.65 22.67 4.36 4.04 7.94
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..